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THE EFFECT OF THE ADMINISTRATION OF THE
ANTICOAGULANT MARCUMAR ON THE BLOOD
COAGULATION MECHANISMS
SHIRLEY A. JOHNSON, Ph.
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AND
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The coumarin type anticoagulants are considered to decrease the plasma levels
of prothrombin and of one other plasma protein related to the coagulation mechanisms,
autoprothrombin I (factor V I I ) \ Autoprothrombin I is believed to drop under
the influence of these drugs before the prothrombin levels begin to fall. However, the
time lag between the changes of each factor varies with the anticoagulant. Recently,
however, Verstraete 1954^ Sise, Kimball and Adamis 1955^ and Johnson and Seegers
1955^ reported a decrease in the plasma levels of autoprothrombin I I (Christmas factor,
Plasma Thromboplastin Component) following the administration of some of these
anticoagulants.

Therapeutic anticoagulant administration is controlled by the Quick one-stage
prothrombin time. This test is influenced by two of the three factors which we know
the anticoagulants alter, but not by all three. There is no known test that will measure
changes in all three factors simultaneously with any appreciable accuracy. The Quick
prothrombin time is still probably the single, most useful, test to use.

Nevertheless,

hemorrhage has been observed in patients with a prothrombin time reduction to only
30-40 per cent of normal according to the Quick test.

This discrepancy between

laboratory findings in anticoagulant control and clinical observations could be due, at
least in part, to changes in plasma levels of autoprothrombin I I which are not observed
in the laboratory using this one routine test.

An effective anticoagulant, which does not affect the plasma levels of autoprothrombin I I , might well be the safest and easiest anticoagulant to control. Marcumar
is an effective anticoagulant. Control of anticoagulant effect by marcumar is noticeably
smoother than with other anticoagulants. This characteristic suggested an absence of
effect on autoprothrombin I I and led to this present investigation.
The role of the various factors which influence the Quick prothrombin time, in
thrombotic disease, has not been fully delineated. It is possible that while the levels
of two factors are measured usually during anticoagulant therapy, the beneficial effect
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of the therapy may be due to the reduction or change in the level of yet another
factor. The results reported here do give us some understanding of the ease of control
of one drug by the usual laboratory procedures.

METHODS
The methods used in this study have been described elsewhere, and are only
briefly mentioned here.
One-stage prothrombin time: This method was described by Quick^
Two-stage prothrombin determination: Ware and Seegers described this test modified
from that of Warner, Brinkhous and Smith'.
Two-stage autoprothrombin I test: This test was developed by Seegers, Johnson and
Penner'.

Two-stage autoprothormbin I I test: This test was first described by Johnson and
Seegers'.

RESULTS
THE PLASMA PROTHROMBIN LEVELS: In about half of the patients followed
under Marcumar therapy, the two-stage prothrombin values did not change during
the first twenty-four hours of therapy. However, in all ten patients the prothrombin
values had dropped on the second day, and all had fallen by the fourth day to 50
u/ml. or below.

THE

AUTOPROTHROMBIN I I LEVELS:

Unlike the anticoagulants studied

previously Marcumar does not reduce the plasma and serum levels of autoprothrombin
I I . The cases were followed for at least fifteen days, and in some cases as long as
twenty-eight days and the autoprothrombin I I levels remained the same throughout.
There is considerable variation in these levels before therapy.

In one case, with

myocardial infarction, no autoprothrombin I I was found in the serum before therapy
began.

THE AUTOPROTHROMBIN I LEVELS: These levels fell in the first day in
every case. The fall in autoprothrombin I alwavs preceded the fall in prothrombin
or coincided with it. As has always been the case, the values for this factor were
found to be higher in serum than in plasma.
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DISCUSSION
Since Marcumar has been found to decrease the plasma levels of autoprothrombin
I and prothrombin, but not autoprothrombin I I , the significance of this latter component
in the treatment of thrombosis can be considered.

It is known that autoprothrombin

I I is deficient in patients with hemophilia B'"". One of our patients sustained a
myocardial infarction in the face of an absence of autoprothrombin I I . There was no
history of hemorrhagic tendency in this case. The anticoagulants Dicumarol, Hedulin,
Tromexan and Sintrom all may reduce the autoprothrombin I I level to practically
zero without patient hemorrhage'^

Conversely, patients may hemorrhage when the

determined prothrombin time is not sufficiently reduced to account for this, and it
has been postulated that a reduction of autoprothrombin I I may be the explanation for
this undesirable effect. Marcumar produces a reasonably stable anticoagulant effect as
measured by the Quick prothrombin time. This observation is enhanced by clinical
experience".

Numerous reports attest to Marcumar as an effective anticoagulant'"''^.".

Since autoprothrombin I I is not reduced by this drug, it is possible that its reduction is
not necessary for effective anticoagulation therapy.

There is another consideration to bear in mind. It has been suggested by O'Brien
that autoprothrombin I I may have a prosthetic group which is phospholipid in nature".
This offers a possible connection between the lipids of blood and the coagulant
mechanisms in the problem of thrombosis. The part played by this factor autoprothrombin I I on the thrombosing tendency is very obscure and difficult to evaluate.

Consider-

ably more time will need to elapse, in all probability, before the study is complete.
CONCLUSIONS
The changes in the plasma levels of the pertinent components in the blood
coagulation mechanisms have been studied in conjunction with the administration of
the anticoagulant, Marcumar. This drug, Marcumar, does not alter the plasma levels
of autoprothrombin I I (PTC, Christmas factor) as does Dicumarol, Tromexan, Hedulin
or Sintrom. The findings may account for the observation that anticoagulant therapy
can be easily controlled with Marcumar as the Quick prothrombin time is the commonly
used laboratory test under these circumstances, and this test is not influenced bv
different levels of autoprothrombin I I . The concepts involving autoprothrombin I I
in the formation of intravascular thrombosis are viewed.
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